Upcoming Medical Conferences in PasadenaSearch Criteria : United States of America Pasadena
Aug 03 - 04, 2019 | Contact Ho 16.00 | USD $661 | Pasadena, California
KSC: Kinetic Shoulder Complex is organized by The Institute of Physical Art, Inc. (IPA) and will be held from Aug 03 - 04, 2019 at Landswick Physical Therapy, Inc., Pasadena, California, United States of America. This Conference has been approved for a maximum of 16 Contact Hours. Audience: PT, PTA, OT, SPT Attendees agree to utilize all skills of evaluation, assessment and treatment learned in this course to the extent allowed under the regulations of their professional practice act. By registering you acknowledge that your attendance does not represent authorization by the IPA, or any of its officers, to utilize any of the material learned which may lie outside of the strict interpretation of your practice act. Purpose: This course is a lab-intensive introduction to the Functional Manual Therapy® system that will train the participants in the management of the Shoulder region. Participants will learn to treat and assess the Thoracic Girdle, Shoulder Girdle, and Intrinsic Motions of the Glenhumoral Joint. Objectives: By the end of the course the participant will; 1) Demonstrate through small group discussion, monitored by the instructor, the ability to list: • The underlying principles of a functional shoulder evaluation • The biomechanical principles which govern shoulder function • The mechanical, neuromuscular, and motor control impairments which can alter efficient shoulder function • The functional interrelationship of the body’s systems and regions necessary for efficient shoulder function 2) Correctly utilize the manual and visual skills necessary to accurately: • Evaluate the functional capacity of the shoulder region • Identify the primary impairments which are limiting functional capacity 3) Perform the manual, observational and problem solving skills to: • Assess the mechanical impairments contributing to the identified limitations of shoulder functional capacity • Assess the neuromuscular CoreFirst strategies necessary for efficient shoulder actions. • Perform appropriate mobilization and re-education treatment to facilitate enhanced shoulder function. 4) Identify through the appropriate manual skills the mechanical, neuromuscular, and motor control impairments and to design and implement a treatment program to restore mobility and functional capacity to the following structures; • First and second rib • Upper Thoracic Spine • Shoulder Girdle • Clavicle • Glenohumeral intrinsic motions • Glenohumeral End of Range motions 5) Demonstrate, through supervised lab practice sessions, the ability to perform the appropriate manual skills to identify and treat impairments of the following structures: • Soft Tissues of the cervicothoracic, shoulder girdle, and glenohumeral regions • Articular Structures of the cervicothoracic, shoulder girdle, and glenohumeral • Neurovascular Structures 6) Perform, through supervised lab practice sessions, the ability to problem solve and utilize the appropriate manual skills of PNF to treat identified impairments of neuromuscular function and motor control for the • Cervicothoracic • Shoulder girdle • Glenohumeral regions 7) Through a case scenario, will develop an appropriate home program, based on shoulder impairments, utilizing the principles of home program development presented in the course. 8) Participate in guided discussions, related to the current evidence for shoulder assessment and treatment. Citing the findings from one recent research article that supports a treatment strategy for the shoulder region. 9) Given a case scenario the participant will DEVELOP three (3) structural and functional goals for patient care.”
Aug 16 - 18, 2019 | CME 15.25 | Pasadena, California
15th Annual California Cancer Consortium Conference (CCC) is organized by Meetings Events & Conference Coordinators, (MECC) and will be held from Aug 16 - 18, 2019 at The Langham, Huntington, Pasadena, Pasadena, California, United States of America. Target Audience: This program will be of interest to medical oncologists, hematologists, surgical oncologists, radiation oncologists, diagnostic radiologists, pulmonologists, urologists, gastroenterologists, pathologists, fellow and resident trainees, advanced care practitioners, registered nurses, physician assistants, pharmacists, clinical research coordinators, biostatisticians, and others involved in oncologic drug development and clinical care. Accreditation: Physician - The Medical Educator Consortium designates this live activity for a maximum of 15.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity “Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 15.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit." Nursing - The Medical Educator Consortium designates this activity for 15.25 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate. Pharmacist - This Application based activity has been approved for 15.25 contact hours (1.52 CEUs) by the Medical Educator Consortium. The Universal Activity Number for this program is JA4008179-9999-19-008-L01-P. Your CE credits will be electronically submitted to CPE Monitor® within 60 days upon successful completion of the activity. Physician Assistant - NCCPA accepts AAPA Category 1 CreditÔ from organizations accredited by ACCME or a recognized state medical society. PAs may claim a maximum of 15.25 Category 1 credits for completing this activity. Needs Assessment: This course was developed in cooperation with the academic faculty and scientists belonging to the California Cancer Consortium to provide an annual in-depth exposure and reviewof newadvancesin cancer drug development, biology, biomarkers, diagnosis, and therapy. The agenda and format was specifically designed to address knowledge gaps identified from prior course participant evaluations and unsolicited comments from practicing oncologists (from private practice, academia) as well as scientists involved in cancer clinical trials. This area of knowledge will be best addressed by an in-depth conference on systemic therapy of malignancies (both solid and hematologic), with ample time provided for interaction by attendees with expert faculty. It is expected that this course will enhance the clinical competence of clinicians and the healthcare team in managing the care of the cancer patient, and subsequently, improve patient outcomes. Course Description: This conference aims to provide up-to-date information to the clinician regarding new advances in cancer biology, diagnosis, and treatment. It will bring together the interprofessional team that include, respected opinion leaders, practicing clinicians and scientists engaged in clinical cancer research to discuss the latest cancer diagnostic and therapeutic advances. Topics focus on the major cancers and drug development areas, including signal transduction/CDK inhibition, angiogenesis inhibition, PI3K/mTOR inhibition, antibody-drug conjugates, and immunotherapy, among others. This annual conference also includes interactive roundtable discussion forums with participation of cancer care experts from the California Cancer Consortium, and features renowned professionals from academia, patient advocacy, government, payer, industry, and business realms of cancer care. Educational Objectives: After participating in this educational activity, you should be able to: • Identify signaling and immunotherapeutic pathwaysthat are involved in the growth and metastases of various tumortypes • Recognizespecificopportunitiesfortherapeutic intervention using an interprofessional team based approach • Describe recent advances in the molecular phenotyping of cancer and relate these to the optimalmanagement of patients with cancer • Based on recent clinicaltrials, assessthe efficacy of noveltherapeutic strategiesin the treatment of patients with cancer • Discuss newand emerging clinicaltrial designs that can test and validate new therapeutic strategies for cancer patients. Additional details will be posted as soon as they are available.
Sep 07 - 10, 2019 | Pasadena, California
American College of Epidemiology (ACE) Annual Meeting Real-World Epidemiologic Evidence in Policy & Practice is organized by American College of Epidemiology (ACE) and will be held from Sep 07 - 10, 2019 at Hilton Pasadena, Pasadena, California, United States of America. Additional details will be posted as soon as they are available.
Sep 07, 2019 | Pasadena, California
Regional Summit Series on Breast Cancer is organized by Oncology Meeting Innovations (OMI) and will be held on Sep 07, 2019 at Pasadena, California, United States of America. Overview: Oncology Meeting Innovations’ (OMI’s) Regional Summit on Breast Cancer is a one-day meeting that engages local community oncologists to discuss the current treatment options in breast cancer. Topics will include recently approved drugs and agents in late-stage development, best practices for employing approved compounds in breast cancer, and relevant case presentations. This meeting will assemble a distinguished group of key opinion leaders to present leading strategies for employing the latest advances, managing risk, and prolonging patient survival. Additionally, the audience will have the opportunity to engage the experts with questions and case-study discussion. Key Topics: • Review optimal management and standards of care for triple negative, ER (+), and HER2 (+) breast cancers. • Discuss the evolving role of genetic alterations and their effects on the management of different types of breast cancer. • Examine newly approved targets in tumor development and growth. • Assess current CDK4/6 and PARP inhibitors and the rationales for combining these inhibitors with other therapies. • Explore the utility of immunotherapy and their combinations for personalizing treatment. Additional details will be posted as soon as they are available.
Oct 30, 2019 | Pasadena, California
2019 Fall Implant Symposium by Southern California Orofacial Academy (SCOA) is organized by Southern California Orofacial Academy (SCOA) and will be held on Oct 30, 2019 at Hilton Pasadena, Pasadena, California, United States of America. Additional details will be posted as soon as they are available.
Aug 14 - 16, 2020 | Pasadena, California
16th Annual California Cancer Consortium Conference (CCC) is organized by Meetings Events & Conference Coordinators, (MECC) and will be held from Aug 14 - 16, 2020 at The Langham, Huntington, Pasadena, Pasadena, California, United States of America. Additional details will be posted as soon as they are available.